Anemia in lung cancer patients;Anémie chez les patients atteints de cancer pulmonaire

Bulletin du Cancer

Volumn 92, Issue 5, 2005, Pages 439-444

  Méric, Jean Baptiste ^a   Morère, Jean François ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Anemia; Erythropoietin; Lung cancer; Transfusion

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; HEMOGLOBIN A;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FATIGUE; HUMAN; LUNG CANCER; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; BLOOD; LUNG TUMOR;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FATIGUE; HEMOGLOBIN A; HUMANS; LUNG NEOPLASMS; PROGNOSIS;

EID: 20344386017     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Auclerc G, Méric JB, Pommeyrol A, Rixe O, Khayat D. Les anémies des cancéreux avant traitement. Bull Cancer 2003; 90: S128-S132.
2. Itri LM. Optimal hemoglobin levels for cancer patients. Sem Oncol 2000; 27(Suppl.4): 12-5.
3. Vogelzang NJ, Breinbart W, Cella D, Curt GA, Groopman JE, Horning SJ. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: result of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997; 34(Suppl. 2): 4-12.
4. Hill C, Doyon F. La fréquence des cancers en France: quoi de neuf depuis l'année dernière. Bull Cancer 2004; 91: 9-14.
5. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res 2001; 105: 31-52.
6. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25(Suppl. 7): 2-6.
7. Pirker R, Wiesenberger K, Pohl G, Minar W, et al. Anemia in lung cancer: clinical impact and management. Clin Lung Cancer 2003; 5: 90-7.
8. Langer JC, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology. Cancer 2002; 95: 613-23.
9. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-34.
10. Barrett-Lee PJ, Bailey NP, OBrien MER, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82: 93-7.
11. Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol 1993; 16: 22-5.
12. Okamoto H, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 1992; 3: 819-24.
13. Rochmann SA, Paul P, Weick JK, Mc Intyre WR, Fantelli F, et al. Effect of cis-diamminedichloroplatinum on erythropoïetin production and hematopoïetic progenitor cells. Int J Cell Cloning 1985; 3: 415-23.
14. Milano G, Caldani C, Khater R, Launay JM, Soummer AM, Namer M, et al. Time- and dose-dependent inhibition of erythrocyte glutathione peroxidase by cisplatin. Biochem Pharmacol 1988; 37: 981-2.
15. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoïetin deficiency syndrome. J Clin Invest 1995; 95: 1650-9.
16. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving ciplatin-based chemotherapy. Cancer 1991; 68: 1101-5.
17. Ray-Coquard I, Bachelot T, Sebban C, Biron P, Guastalla JP, Blay JY. Anémie et chimiothérapie. Bull Cancer 2003; 90: S133-S143.
18. Abels RI. Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol 1992; 87(Suppl. 1): 4-11.
19. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J 1995: 899-909.
20. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med 2002; 346: 92-8.
21. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non small cell lung cancer. J Clin Oncol 2000; 18: 2529-36.
22. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samarkos E, Boukovinas J, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20: 3578-85.
23. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Manage 1997; 13: 63-74.
24. Sarna L. Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum 1998; 25: 1041-8.
25. Stone P, Richard M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11: 561-7.
26. Langer JC, Hirsch FR, Cortés-Funes H, Sawyer ST, Thatcher N. Targeted molecular mechanisms of epoetin alfa. Lung Cancer 2003; 41: S133-S135.
27. Spaeth D, Casedevall N, Daouphars M, Marchal C, Marec-Berard P, Fahre N, et al. Recommandations pour la pratique clinique: Standards, Options et Recommandations 2003 pour lutilisation de lérythropoïétine recombinante (époétine alfa et bêta, darbepoetine alfa, EPO) dans la prise en charge de lanémie en cancérologie. Bull Cancer 2003; 91: 179-88.
28. Anaes (Agence nationale daccréditation et dévaluation en santé). Indications et contre-indications des transfusions et produits sanguins labiles. Recommandations pour la pratique clinique. Paris: EDK, 1998; [156].
29. Estrin JT, Schocket L, Kregenow R, Henry DH. A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 1999; 4: 318-24.
30. Soria JC, Brisgand D, Le Chevalier T. Do all patients with non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 2001; 12: 1667-70.
31. Caro JJ, Sabs M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.
32. Feld R, Abratt R, Graziano S, Jassem J, Lacquet L, Niname V, et al. Pre-treatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 1997; 17(Suppl. 1): S3-S10.
33. Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analysis including recursive partitioning and amalgamation. Lung Cancer 1996; 15: 67-77.
34. Mac Rae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002; 64: 37-40.
35. Albain KS, Crowley JJ, LeBlanc M. Survival determinants in extensive-stage non-small cell lung cancer: the southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
36. Spaeth D, Principes généraux du traitement de l'anémie des patients cancéreux. Bull Cancer 2002; 89: 935-47.
37. Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portenoy RK, Cremieux PY, et al. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 1999; 18: 574a.
38. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412-25.
39. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin-alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemothetapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-34.
40. Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82.
41. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80: 396-402.
42. Vansteenkist J, Pirker R, Massuti B. Double-blind, placebo-controlled, randomized phase III trial of darbepoietin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-20.
43. Kunikane H, Watanabe K, Fukuoka M. Double-blind randomized controlled trial of the effect of recombinant human erythropoietin alfa on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001; 6: 296-301.
44. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-107.
45. Van Acht MJ, Hermans J, Boks DE, et al. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992; 23: 229-35.
46. Evans J, Bergso P. The influence of anaemia on the results of radiotherapy in carcinoma of the cervix. Radiology 1965; 48: 709-17.
47. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-15.
48. Antonadou D, Cardamakis E, Sarris G. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiather Oncol 1998; 48(S122): 483.
49. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schlichet B, et al. Erythcopoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
50. Littlewood TJ, Bajetra E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
51. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-8.
52. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346: 85-91.